晚期胆囊癌 (GBC) 一线化疗 (CT) 后巩固化放疗 (CTRT) 与观察的随机研究:RACE-GB 研究。

IF 6.4 1区 医学 Q1 ONCOLOGY
Sushma Agrawal, Vishwas Kapoor, Rahul Rahul, Ashish Singh, Prabhakar Mishra, Rajan Saxena
{"title":"晚期胆囊癌 (GBC) 一线化疗 (CT) 后巩固化放疗 (CTRT) 与观察的随机研究:RACE-GB 研究。","authors":"Sushma Agrawal, Vishwas Kapoor, Rahul Rahul, Ashish Singh, Prabhakar Mishra, Rajan Saxena","doi":"10.1016/j.ijrobp.2024.11.099","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>CT is the standard of care for patients presenting with unresectable advanced GBC but their prognosis remains poor. The value of consolidation CTRT after initial CT is uncertain. We therefore conducted a single centre open label randomised trial evaluating consolidation CTRT versus Observation after four cycles of CT in patients whose disease did not progress during CT (partial responders/stable disease).</p><p><strong>Materials & methods: </strong>Responders to 4 cycles of CT were randomised (1:1) to CTRT versus Observation (n=135). CTRT was delivered by 3D-Conformal Radiation Therapy (Field in field when required) along-with concurrent capecitabine. The dose of RT was 45 Gy in 25 fractions to GBC and lymphatics followed by a boost of 9 Gy in 5 fractions to the GBC. The primary endpoint was overall survival which was calculated from the date of randomisation.</p><p><strong>Results: </strong>67 patients were randomized to observation and 68 to CTRT. Consolidation CTRT led to an improvement in median overall survival from 4 months to 10 months (HR 0.43; 95% CI, 0.32 to 0.62; P < 0.001). The actual median OS from accrual was 7 months (95%CI 6.114 to 7.88) versus 13 months (95% CI 11.13 months to 14.84 months). Adverse events (grade 3 or higher) due to CTRT were nausea: 3%, anaemia: 9%, GI bleed: 5.8%, hepatotoxicity:13%. FACT G score and FACT Hep score did not deteriorate due to CTRT as compared to observation (p value 0.053 and 0.097).</p><p><strong>Conclusion: </strong>To our knowledge, this is the first-ever randomized study in LMIC setting to demonstrate that consolidation CTRT significantly prolonged overall survival without deterioration in QOL and should be the alternative standard of care in advanced unresectable GBC.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Randomized Study of Consolidation Chemoradiation (CTRT) versus Observation after first line chemotherapy (CT) in Advanced Gall bladder Cancers (GBC):RACE-GB study.\",\"authors\":\"Sushma Agrawal, Vishwas Kapoor, Rahul Rahul, Ashish Singh, Prabhakar Mishra, Rajan Saxena\",\"doi\":\"10.1016/j.ijrobp.2024.11.099\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>CT is the standard of care for patients presenting with unresectable advanced GBC but their prognosis remains poor. The value of consolidation CTRT after initial CT is uncertain. We therefore conducted a single centre open label randomised trial evaluating consolidation CTRT versus Observation after four cycles of CT in patients whose disease did not progress during CT (partial responders/stable disease).</p><p><strong>Materials & methods: </strong>Responders to 4 cycles of CT were randomised (1:1) to CTRT versus Observation (n=135). CTRT was delivered by 3D-Conformal Radiation Therapy (Field in field when required) along-with concurrent capecitabine. The dose of RT was 45 Gy in 25 fractions to GBC and lymphatics followed by a boost of 9 Gy in 5 fractions to the GBC. The primary endpoint was overall survival which was calculated from the date of randomisation.</p><p><strong>Results: </strong>67 patients were randomized to observation and 68 to CTRT. Consolidation CTRT led to an improvement in median overall survival from 4 months to 10 months (HR 0.43; 95% CI, 0.32 to 0.62; P < 0.001). The actual median OS from accrual was 7 months (95%CI 6.114 to 7.88) versus 13 months (95% CI 11.13 months to 14.84 months). Adverse events (grade 3 or higher) due to CTRT were nausea: 3%, anaemia: 9%, GI bleed: 5.8%, hepatotoxicity:13%. FACT G score and FACT Hep score did not deteriorate due to CTRT as compared to observation (p value 0.053 and 0.097).</p><p><strong>Conclusion: </strong>To our knowledge, this is the first-ever randomized study in LMIC setting to demonstrate that consolidation CTRT significantly prolonged overall survival without deterioration in QOL and should be the alternative standard of care in advanced unresectable GBC.</p>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijrobp.2024.11.099\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.11.099","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Randomized Study of Consolidation Chemoradiation (CTRT) versus Observation after first line chemotherapy (CT) in Advanced Gall bladder Cancers (GBC):RACE-GB study.

Purpose: CT is the standard of care for patients presenting with unresectable advanced GBC but their prognosis remains poor. The value of consolidation CTRT after initial CT is uncertain. We therefore conducted a single centre open label randomised trial evaluating consolidation CTRT versus Observation after four cycles of CT in patients whose disease did not progress during CT (partial responders/stable disease).

Materials & methods: Responders to 4 cycles of CT were randomised (1:1) to CTRT versus Observation (n=135). CTRT was delivered by 3D-Conformal Radiation Therapy (Field in field when required) along-with concurrent capecitabine. The dose of RT was 45 Gy in 25 fractions to GBC and lymphatics followed by a boost of 9 Gy in 5 fractions to the GBC. The primary endpoint was overall survival which was calculated from the date of randomisation.

Results: 67 patients were randomized to observation and 68 to CTRT. Consolidation CTRT led to an improvement in median overall survival from 4 months to 10 months (HR 0.43; 95% CI, 0.32 to 0.62; P < 0.001). The actual median OS from accrual was 7 months (95%CI 6.114 to 7.88) versus 13 months (95% CI 11.13 months to 14.84 months). Adverse events (grade 3 or higher) due to CTRT were nausea: 3%, anaemia: 9%, GI bleed: 5.8%, hepatotoxicity:13%. FACT G score and FACT Hep score did not deteriorate due to CTRT as compared to observation (p value 0.053 and 0.097).

Conclusion: To our knowledge, this is the first-ever randomized study in LMIC setting to demonstrate that consolidation CTRT significantly prolonged overall survival without deterioration in QOL and should be the alternative standard of care in advanced unresectable GBC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信